SMO and skin basal cell carcinoma: Although multiple reasons may account for the lack of objective responses to SMOi in several clinical trials, we propose here that SMO-independent activation of oncogenic GLI activity represents an important and frequent cause for the often disappointing results in patients with cancers other than BCC, MB or AML.